Format

Send to

Choose Destination
Curr Opin Immunol. 2009 Feb;21(1):23-9. doi: 10.1016/j.coi.2009.01.004. Epub 2009 Feb 24.

Mechanism of action of clinically approved adjuvants.

Author information

1
Department of Respiratory Diseases, University of Ghent, De Pintelaan, Belgium. bart.lambrecht@ugent.be

Abstract

Aluminum-containing adjuvants continue to be the most widely used adjuvants for human use. In the last year a major breakthrough has been the realization that alum adjuvant triggers an ancient pathway of innate recognition of crystals in monocytes and triggers them to become immunogenic dendritic cells, nature's adjuvant. This recognition can occur directly, via the triggering of the NALP3 inflammasome by alum crystals, or indirectly through release of the endogenous danger signal uric acid. It is also clear now that adjuvants trigger the stromal cells at the site of injection, leading to the necessary chemokines that attract the innate immune cells to the site of injection. How exactly these pathways interact remains to be determined.

Comment in

PMID:
19246182
DOI:
10.1016/j.coi.2009.01.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center